These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 38685112)
1. Correction: TP63 truncating mutation causes increased cell apoptosis and premature ovarian insufficiency by enhanced transcriptional activation of CLCA2. Fan Y; Chen S; Chu C; Yin X; Jin J; Zhang L; Yan H; Cao Z; Liu R; Xin M; Li L; Yin C J Ovarian Res; 2024 Apr; 17(1):93. PubMed ID: 38685112 [No Abstract] [Full Text] [Related]
2. TP63 truncating mutation causes increased cell apoptosis and premature ovarian insufficiency by enhanced transcriptional activation of CLCA2. Fan Y; Chen S; Chu C; Yin X; Jin J; Zhang L; Yan H; Cao Z; Liu R; Xin M; Li L; Yin C J Ovarian Res; 2024 Mar; 17(1):67. PubMed ID: 38528613 [TBL] [Abstract][Full Text] [Related]
3. TP63-truncating variants cause isolated premature ovarian insufficiency. Tucker EJ; Jaillard S; Grover SR; van den Bergen J; Robevska G; Bell KM; Sadedin S; Hanna C; Dulon J; Touraine P; Sinclair AH Hum Mutat; 2019 Jul; 40(7):886-892. PubMed ID: 30924587 [TBL] [Abstract][Full Text] [Related]
4. A homozygous NOBOX truncating variant causes defective transcriptional activation and leads to primary ovarian insufficiency. Li L; Wang B; Zhang W; Chen B; Luo M; Wang J; Wang X; Cao Y; Kee K Hum Reprod; 2017 Jan; 32(1):248-255. PubMed ID: 27836978 [TBL] [Abstract][Full Text] [Related]
5. Dominant TP63 missense variants lead to constitutive activation and premature ovarian insufficiency. Tucker EJ; Gutfreund N; Belaud-Rotureau MA; Gilot D; Brun T; Kline BL; Bell KM; Domin-Bernhard M; Théard C; Touraine P; Robevska G; van van den Bergen J; Ayers KL; Sinclair AH; Dötsch V; Jaillard S Hum Mutat; 2022 Oct; 43(10):1443-1453. PubMed ID: 35801529 [TBL] [Abstract][Full Text] [Related]
7. CLCA2, a target of the p53 family, negatively regulates cancer cell migration and invasion. Sasaki Y; Koyama R; Maruyama R; Hirano T; Tamura M; Sugisaka J; Suzuki H; Idogawa M; Shinomura Y; Tokino T Cancer Biol Ther; 2012 Dec; 13(14):1512-21. PubMed ID: 22990203 [TBL] [Abstract][Full Text] [Related]
8. CLCA2: A Potential Guardian against Premature Senescence and Skin Aging. Guerrero-Navarro L; Martic I; Ploner C; Jansen-Dürr P; Cavinato M Biomedicines; 2024 Mar; 12(3):. PubMed ID: 38540205 [TBL] [Abstract][Full Text] [Related]
9. Analysis of NR5A1 in 142 patients with premature ovarian insufficiency, diminished ovarian reserve, or unexplained infertility. Jaillard S; Sreenivasan R; Beaumont M; Robevska G; Dubourg C; Knarston IM; Akloul L; van den Bergen J; Odent S; Croft B; Jouve G; Grover SR; Duros S; Pimentel C; Belaud-Rotureau MA; Ayers KL; Ravel C; Tucker EJ; Sinclair AH Maturitas; 2020 Jan; 131():78-86. PubMed ID: 31787151 [TBL] [Abstract][Full Text] [Related]
10. A newly identified missense mutation in CLCA2 is associated with autosomal dominant cardiac conduction block. Mao Z; Wang Y; Peng H; He F; Zhu L; Huang H; Huang X; Lu X; Tan X Gene; 2019 Sep; 714():143990. PubMed ID: 31326550 [TBL] [Abstract][Full Text] [Related]
11. Epigenetic Repression of Chloride Channel Accessory 2 Transcription in Cardiac Fibroblast: Implication in Cardiac Fibrosis. Shao T; Xue Y; Fang M Front Cell Dev Biol; 2021; 9():771466. PubMed ID: 34869368 [TBL] [Abstract][Full Text] [Related]
12. CLCA2 epigenetic regulation by CTBP1, HDACs, ZEB1, EP300 and miR-196b-5p impacts prostate cancer cell adhesion and EMT in metabolic syndrome disease. Porretti J; Dalton GN; Massillo C; Scalise GD; Farré PL; Elble R; Gerez EN; Accialini P; Cabanillas AM; Gardner K; De Luca P; De Siervi A Int J Cancer; 2018 Aug; 143(4):897-906. PubMed ID: 29536528 [TBL] [Abstract][Full Text] [Related]
14. CLCA2 tumour suppressor gene in 1p31 is epigenetically regulated in breast cancer. Li X; Cowell JK; Sossey-Alaoui K Oncogene; 2004 Feb; 23(7):1474-80. PubMed ID: 14973555 [TBL] [Abstract][Full Text] [Related]
15. CLCA2 overexpression suppresses epithelial-to-mesenchymal transition in cervical cancer cells through inactivation of ERK/JNK/p38-MAPK signaling pathways. Xin W; Zhang J; Zhang H; Ma X; Zhang Y; Li Y; Wang F BMC Mol Cell Biol; 2022 Oct; 23(1):44. PubMed ID: 36280802 [TBL] [Abstract][Full Text] [Related]
16. Transport of CLCA2 to the nucleus by extracellular vesicles controls keratinocyte survival and migration. Seltmann K; Hettich B; Abele S; Gurri S; Mantella V; Leroux JC; Werner S J Extracell Vesicles; 2024 Apr; 13(4):e12430. PubMed ID: 38602325 [TBL] [Abstract][Full Text] [Related]
17. How polymorphic markers contribute to genetic diseases in different populations? The study of inhibin A for premature ovarian insufficiency. Christofolini DM; Cordts EB; Santos-Pinheiro F; Kayaki EA; Dornas MCF; Santos MC; Bianco B; Barbosa CP Einstein (Sao Paulo); 2017; 15(3):269-272. PubMed ID: 29091146 [TBL] [Abstract][Full Text] [Related]
18. High-resolution array-CGH analysis on 46,XX patients affected by early onset primary ovarian insufficiency discloses new genes involved in ovarian function. Bestetti I; Castronovo C; Sironi A; Caslini C; Sala C; Rossetti R; Crippa M; Ferrari I; Pistocchi A; Toniolo D; Persani L; Marozzi A; Finelli P Hum Reprod; 2019 Mar; 34(3):574-583. PubMed ID: 30689869 [TBL] [Abstract][Full Text] [Related]
19. Along with its favorable prognostic role, CLCA2 inhibits growth and metastasis of nasopharyngeal carcinoma cells via inhibition of FAK/ERK signaling. Qiang YY; Li CZ; Sun R; Zheng LS; Peng LX; Yang JP; Meng DF; Lang YH; Mei Y; Xie P; Xu L; Cao Y; Wei WW; Cao L; Hu H; Yang Q; Luo DH; Liang YY; Huang BJ; Qian CN J Exp Clin Cancer Res; 2018 Feb; 37(1):34. PubMed ID: 29463274 [TBL] [Abstract][Full Text] [Related]
20. GAPO syndrome: a new syndromic cause of premature ovarian insufficiency. Benetti-Pinto CL; Ferreira V; Andrade L; Yela DA; De Mello MP Climacteric; 2016 Dec; 19(6):594-598. PubMed ID: 27426988 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]